Merck/Schering Vytorin Launch Could Be Aided By New Cholesterol Guidelines
Revised cholesterol treatment guidelines could result in increased use of combination lipid-lowering therapies as Merck/Schering-Plough's Vytorin enters the market
Revised cholesterol treatment guidelines could result in increased use of combination lipid-lowering therapies as Merck/Schering-Plough's Vytorin enters the market